{"id":"oxyneo","safety":{"commonSideEffects":[{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Drowsiness"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"OxyNEO uses a proprietary polymer matrix technology that makes the tablet resistant to physical and chemical manipulation, reducing the potential for misuse via snorting or injection. The formulation maintains the pharmacokinetic profile of oxycodone as a mu-opioid receptor agonist for pain relief while adding abuse-deterrent properties. This approach aims to reduce diversion and non-medical use while preserving therapeutic benefit for legitimate pain management.","oneSentence":"OxyNEO is an extended-release formulation of oxycodone designed to deter abuse by resisting crushing, dissolving, and extraction while maintaining analgesic efficacy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:35:32.680Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe pain requiring around-the-clock opioid therapy"}]},"trialDetails":[{"nctId":"NCT02101840","phase":"PHASE4","title":"Abuse Liability of Controlled-Release Oxycodone Formulations","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2014-02","conditions":"Substance-Related Disorders","enrollment":11}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Oxycodone"],"phase":"marketed","status":"active","brandName":"OxyNEO®","genericName":"OxyNEO®","companyName":"Centre for Addiction and Mental Health","companyId":"centre-for-addiction-and-mental-health","modality":"Small molecule","firstApprovalDate":"","aiSummary":"OxyNEO is an extended-release formulation of oxycodone designed to deter abuse by resisting crushing, dissolving, and extraction while maintaining analgesic efficacy. Used for Moderate to severe pain requiring around-the-clock opioid therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}